Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

NCT05733689 · View on ClinicalTrials.gov ↗

Study Summary

This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

Interventions

  • COMBINATION_PRODUCT FLOT
  • COMBINATION_PRODUCT FOLFOX
  • COMBINATION_PRODUCT FOLFIRI
  • COMBINATION_PRODUCT FOLFIRINOX
  • COMBINATION_PRODUCT PACLITAXEL with or without CARBOPLATIN

Study Locations (1)

California

  • Chao Family Comprehensive Cancer Center, University — Orange

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-06-27
Est. Completion 2027-06
Phase Phase 1

Sponsor

University of California, Irvine

353 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05733689

The ClinicalTrials.gov registry entry for NCT05733689 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 353 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions — of which FLOT is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05733689 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05733689 about?

NCT05733689 is a clinical study titled "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)". This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

What is the current status of trial NCT05733689?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-27. Estimated completion is 2027-06.

What conditions does trial NCT05733689 study?

This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05733689?

The interventions under investigation include: FLOT (COMBINATION_PRODUCT), FOLFOX (COMBINATION_PRODUCT), FOLFIRI (COMBINATION_PRODUCT), FOLFIRINOX (COMBINATION_PRODUCT), PACLITAXEL with or without CARBOPLATIN (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05733689?

This trial is sponsored by University of California, Irvine, which has 353 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05733689 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial